In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.

中文翻译：

---

Benralizumab 对于 EGPA 的治疗效果不劣于美泊利单抗

在两种针对 IL-5 或其受体的药物的头对头 III 期试验中，在诱导嗜酸性肉芽肿性多血管炎患者缓解方面，贝那利珠单抗并不劣于美泊利单抗。